OptimizeRx vs Outdoor
OPRX and POWW side by side, both in miscellaneous business services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OPRX and POWW compare
Outdoor is the larger company, worth 2.2 times as much as OptimizeRx ($290M against $131M).
On earnings, OptimizeRx is cheaper: it trades at 28.9× trailing earnings, against 83.3× for Outdoor.
Outdoor grew revenue faster over the last twelve months (9.7% versus −5.8% for OptimizeRx).
Outdoor keeps more of each dollar of sales as profit, with a net margin of 12.1% compared with 4.7% at OptimizeRx.
Outdoor scores higher on the StockData Score (11 against 10 for OptimizeRx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OPRX | POWW |
|---|---|---|
| Size and price | ||
| Market cap | $131M | $290M |
| Share price | $6.94 | $2.50 |
| Change, 1 year | −54.3% | 39.7% |
| Change, 5 years | −89.9% | −60.0% |
| Beta (5Y) | 1.50 | 0.73 |
| Employees | 104 | 63 |
| StockData Score | ||
| Total score | 10 | 11 (better) |
| Valuation score | 3 (better) | 2 |
| Growth score | 2 (better) | 1 |
| Performance score | 2 | 2 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 28.9× (better) | 83.3× |
| P/S | 1.3× (better) | 5.4× |
| P/B | 1.0× (better) | 1.2× |
| EV/EBITDA | 8.3× (better) | 12.6× |
| P/FCF | 7.1× (better) | 30.9× |
| FCF yield | 14.0% (better) | 3.2% |
| Fair value | $9.96 | $1.97 |
| Margin of safety | 30.4% (better) | −27.2% |
| Growth | ||
| Revenue growth (TTM) | −5.8% | 9.7% (better) |
| Revenue growth, 5Y average | 20.4% (better) | −3.9% |
| Profitability | ||
| Gross margin | 73.2% | 86.5% (better) |
| Operating margin | 11.1% (better) | 5.6% |
| Net margin | 4.7% | 12.1% (better) |
| FCF margin | 18.6% (better) | 17.5% |
| Return on equity | 3.7% (better) | 2.8% |
| Return on invested capital | 5.8% (better) | 1.5% |
| Financial health | ||
| Debt / equity | 0.15 (better) | 0.00 |
| Net debt / EBITDA | −0.33 | – |
| Interest coverage | 2.3× | – |
| Current ratio | 5.58 (better) | 4.74 |
| Altman Z-score | 2.82 | 5.52 (better) |
| Piotroski F-score | 8 (better) | 7 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.07% |
| Shareholder yield | 0.00% | 0.07% (better) |
| Ownership | ||
| Held by institutions | 59.6% | 58.8% |
| Held by insiders | 19.4% | 43.9% |
| Insider net buying, 12 months | −$18.8K | – |
| Short interest, % of float | 7.8% | – |
Go deeper
- OPRX stock overview
- OPRX income statement
- OPRX valuation and score
- POWW stock overview
- POWW income statement
- POWW valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.